534 related articles for article (PubMed ID: 27671545)
21. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Numans ME; Bonis PA; Lau J
Cochrane Database Syst Rev; 2006 Jul; (3):CD002095. PubMed ID: 16855986
[TBL] [Abstract][Full Text] [Related]
22. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
van Pinxteren B; Numans ME; Bonis PA; Lau J
Cochrane Database Syst Rev; 2004 Oct; (4):CD002095. PubMed ID: 15495027
[TBL] [Abstract][Full Text] [Related]
23. Review article: treatment of mild and severe cases of GERD.
Tytgat GN
Aliment Pharmacol Ther; 2002 Jul; 16 Suppl 4():73-8. PubMed ID: 12047264
[TBL] [Abstract][Full Text] [Related]
24. Randomised clinical trial: the clinical efficacy and safety of an alginate-antacid (Gaviscon Double Action) versus placebo, for decreasing upper gastrointestinal symptoms in symptomatic gastroesophageal reflux disease (GERD) in China.
Sun J; Yang C; Zhao H; Zheng P; Wilkinson J; Ng B; Yuan Y
Aliment Pharmacol Ther; 2015 Oct; 42(7):845-54. PubMed ID: 26228097
[TBL] [Abstract][Full Text] [Related]
25. Medical treatments of GERD: the old and new.
Vela MF
Gastroenterol Clin North Am; 2014 Mar; 43(1):121-33. PubMed ID: 24503363
[TBL] [Abstract][Full Text] [Related]
26. Comparison of acid-lowering drugs for endoscopy negative reflux disease: Systematic review and network Meta-Analysis.
Barberio B; Visaggi P; Savarino E; de Bortoli N; Black CJ; Ford AC
Neurogastroenterol Motil; 2023 Jan; 35(1):e14469. PubMed ID: 36153790
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of proton-pump inhibitors in children with gastroesophageal reflux disease: a systematic review.
van der Pol RJ; Smits MJ; van Wijk MP; Omari TI; Tabbers MM; Benninga MA
Pediatrics; 2011 May; 127(5):925-35. PubMed ID: 21464183
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of histamine-2 receptor antagonists.
van der Pol R; Langendam M; Benninga M; van Wijk M; Tabbers M
JAMA Pediatr; 2014 Oct; 168(10):947-54. PubMed ID: 25133940
[TBL] [Abstract][Full Text] [Related]
29. Tailored therapy guided by multichannel intraluminal impedance pH monitoring for refractory non-erosive reflux disease.
Ranaldo N; Losurdo G; Iannone A; Principi M; Barone M; De Carne M; Ierardi E; Di Leo A
Cell Death Dis; 2017 Sep; 8(9):e3040. PubMed ID: 28880273
[TBL] [Abstract][Full Text] [Related]
30. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease.
Sigterman KE; van Pinxteren B; Bonis PA; Lau J; Numans ME
Cochrane Database Syst Rev; 2013 May; 2013(5):CD002095. PubMed ID: 23728637
[TBL] [Abstract][Full Text] [Related]
31. Treatment of gastroesophageal reflux disease.
Fass R; Bautista J; Janarthanan S
Clin Cornerstone; 2003; 5(4):18-29; discussion 30-1. PubMed ID: 15101492
[TBL] [Abstract][Full Text] [Related]
32. A cost-effectiveness analysis of prescribing strategies in the management of gastroesophageal reflux disease.
Gerson LB; Robbins AS; Garber A; Hornberger J; Triadafilopoulos G
Am J Gastroenterol; 2000 Feb; 95(2):395-407. PubMed ID: 10685741
[TBL] [Abstract][Full Text] [Related]
33. An alginate-antacid formulation localizes to the acid pocket to reduce acid reflux in patients with gastroesophageal reflux disease.
Rohof WO; Bennink RJ; Smout AJ; Thomas E; Boeckxstaens GE
Clin Gastroenterol Hepatol; 2013 Dec; 11(12):1585-91; quiz e90. PubMed ID: 23669304
[TBL] [Abstract][Full Text] [Related]
34. Partnership in optimizing management of reflux symptoms: a treatment algorithm for over-the-counter proton-pump inhibitors.
Boardman HF; Delaney BC; Haag S
Curr Med Res Opin; 2015; 31(7):1309-18. PubMed ID: 25950642
[TBL] [Abstract][Full Text] [Related]
35. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
36. The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: a meta-analysis.
Xi L; Zhu J; Zhang H; Muktiali M; Li Y; Wu A
Esophagus; 2021 Jan; 18(1):144-151. PubMed ID: 32519226
[TBL] [Abstract][Full Text] [Related]
37. Novel pharmaceutical approaches to reflux disease.
Dutta U; Armstrong D
Gastroenterol Clin North Am; 2013 Mar; 42(1):93-117. PubMed ID: 23452633
[TBL] [Abstract][Full Text] [Related]
38. New therapeutic options in the treatment of GERD and other acid-peptic disorders. Based on a presentation by Duane D. Webb, MD, FACG.
Am J Manag Care; 2000 May; 6(9 Suppl):S467-75. PubMed ID: 10977486
[TBL] [Abstract][Full Text] [Related]
39. Treatment patterns in paediatric patients with a new diagnosis of gastroesophageal reflux disease.
Ruigómez A; Hungin AP; Lundborg P; Johansson S; Wallander MA; García Rodríguez LA
Eur J Gastroenterol Hepatol; 2011 Mar; 23(3):232-7. PubMed ID: 21258240
[TBL] [Abstract][Full Text] [Related]
40. Drugs, bugs, and esophageal pH profiles.
Robinson M
Yale J Biol Med; 1999; 72(2-3):169-72. PubMed ID: 10780578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
